Pacific Biosciences Reports Q2 Revenue Of $39 Million And TychoBio AI Partnership
Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported second-quarter 2026 revenue of $39 million alongside a GAAP net loss of $0.14 per share. The life sciences technology developer also narrowed its full-year revenue outlook to between $155 million and $165 million, while holding $236.9 million in total cash and investments at the end of June.
Alongside its financial metrics, the company announced a collaboration with TychoBio to build large-scale genomic datasets. The partnership aims to process more than 10,000 RNA samples using PacBio HiFi and Kinnex long-read sequencing tools. These full-length RNA datasets will be used to train artificial intelligence models designed for developing RNA-based therapeutics, expanding the practical reach of long-read sequencing in drug discovery.
Investors will be monitoring whether the company can hit the mid-point of its refined annual revenue range while managing cash burn. Furthermore, market participants will watch for future commercial developments or strategic updates stemming from the TychoBio collaboration, even though financial terms for the partnership were not disclosed.
Key points
- Pacific Biosciences of California, Inc. (NASDAQ:PACB) generated $39 million in Q2 2026 revenue with a GAAP loss of $0.14 per share.
- Full-year 2026 revenue guidance was narrowed to a range of $155 million to $165 million.
- The company finished June with $236.9 million in cash and investments on its balance sheet.
- A new collaboration with TychoBio will generate 10,000+ RNA datasets using PacBio HiFi and Kinnex sequencing for AI therapeutic model training.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were Pacific Biosciences Q2 2026 financial results?
Pacific Biosciences reported Q2 2026 revenue of $39 million and a GAAP loss of $0.14 per share, ending June with $236.9 million in cash and investments.
What is Pacific Biosciences updated revenue guidance for 2026?
The company narrowed its full-year 2026 revenue guidance to between $155 million and $165 million.
What is the Pacific Biosciences partnership with TychoBio?
Pacific Biosciences is partnering with TychoBio to generate full-length RNA datasets from over 10,000 samples using HiFi and Kinnex sequencing to train AI for RNA therapeutic design.